Keyphrases
Antiretroviral Therapy
100%
COVID-19
37%
CD4 Count
36%
Strategic Timing
21%
Confidence Interval
20%
Neutralizing Monoclonal Antibody
19%
Placebo
18%
COVID-19 Treatment
18%
Bone Mineral Density
17%
Clinical Outcomes
16%
AIDS/HIV
16%
Randomized Trial
16%
Hospitalized Patients
15%
Interleukin-6
14%
Non-AIDS Comorbidities
14%
HIV Viral Load
14%
Hazard Ratio
13%
Cell Count
13%
Randomized Controlled Trial
13%
SMART Study
13%
D-dimer
13%
Continuous Therapy
13%
HIV Infection
12%
Treatment Trials
12%
Patients with COVID-19
10%
Placebo Groups
10%
Opportunistic Diseases
10%
People Living with HIV (PLHIV)
10%
Viral Suppression
9%
Remdesivir
9%
Human Immunodeficiency Virus Infection
9%
Ebola Virus Disease
9%
Bone Loss
9%
HIV-infected Adults
9%
CD4+
8%
Nave
8%
Cardiovascular Disease
8%
HIV-1 Infection
8%
Kernel Estimator
8%
Bandwidth Selection
8%
Therapeutic Monoclonal Antibody
8%
Randomized Double-blind
8%
Cardiovascular Risk
8%
Placebo-controlled
8%
HIV Prevention
8%
Immunological Biomarkers
8%
Master Protocol
8%
Zaire Ebolavirus
8%
Neurocognitive Function
8%
CD4+ T
7%
Medicine and Dentistry
Antiretroviral Therapy
61%
Human Immunodeficiency Virus
44%
Cell Count
22%
COVID-19
21%
Bone Density
19%
Placebo
17%
Human Immunodeficiency Virus Infection
16%
Diseases
12%
Cardiovascular Disease
11%
Osteolysis
8%
Ebolavirus
8%
Acquired Immune Deficiency Syndrome
7%
Hazard Ratio
7%
Arm
7%
Virus Infection
6%
Remdesivir
6%
Virus RNA
6%
T-Helper Cell
5%
Treatment Interruption
5%
Abdominal Fat
5%
Treatment Group
5%
Computer Assisted Tomography
5%
Ebola Vaccine
5%
Randomized Controlled Trial
5%
